Gastric cancers are malignant tumors arising in the stomach, most commonly adenocarcinomas originating from gastric mucosa. Clinical presentation can be nonspecific in early stages, and many patients are diagnosed at advanced stages. Disease burden remains substantial worldwide.
The US FDA granted priority review and the European Medicines Agency validated applications for Enhertu as post-neoadjuvant treatment for HER2-positive early breast cancer, based on Phase III trial data showing 53% reduction in recurrence risk.
A comprehensive market report reveals over 180 companies are developing more than 200 PD-1 and PD-L1 inhibitor drugs, with recent fast-track designations and successful Phase III trial results driving expansion in cancer immunotherapy.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07219238 |
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) |
RECRUITING | PHASE2/PHASE3 |
| NCT07003334 |
Correlation of Psychological Distress and Immune Checkpoint Inhibitors in Gastric Cancer |
RECRUITING | |
| NCT06895447 |
Robotic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Therapy |
RECRUITING | PHASE2 |
| NCT06856382 |
The Association Between Microplastics and Macrogenomics and Metabolomics in Gastric Cancer |
ACTIVE_NOT_RECRUITING | |
| NCT06854146 |
The Effect of Environmental Factors on Gastric Cancer Based on Macrogenome |
ACTIVE_NOT_RECRUITING | |
| NCT06822413 |
Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis |
RECRUITING | |
| NCT06807372 |
Validation of a Model for Predicting Duodenal Stump Leakage After Gastrectomy |
ACTIVE_NOT_RECRUITING | |
| NCT06766305 |
QL1706 Combined With SOX Used in Theperioperative Treatment |
RECRUITING | PHASE1/PHASE2 |
| NCT06728878 |
Analysis of Lymph Node Metastasis and Tumor Deposit in the Short Gastric Mesentery Following Total Gastrectomy for Gastric Cancer |
RECRUITING | |
| NCT06706466 |
Evaluate the Prognostic Significance of Changes in the Systemic Immune-Inflammation Index in Patients with AGC Treated with ICI Therapy. |
COMPLETED |
